Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Formycon: H1 2026 revenue nearly tripled, adjusted EBITDA significantly improved

Formycon reports that first-half 2026 revenue nearly tripled year-on-year and adjusted EBITDA improved to -6.9 Mio. EUR (previously -19.2 Mio. EUR). Drivers were milestone payments (14.3 Mio. EUR) and stronger commercial sales, with FYB206 accounting for more than 40% of revenue. Cash resources fell to 51.8 Mio. EUR, and total assets amount to 714 Mio. EUR. Management confirmed the full-year guidance but warned of non-linear revenue timing and competitive risks in the biosimilar market. » Altro su de.investing.com
Formycon raises half‑year revenue to €25.8m and reduces EBITDA loss

Formycon reports H1 2026 revenue of €25.8m and a reduced EBITDA loss of €3.4m. Growth was driven by milestone and advance payments from partnerships for FYB206 as well as increased licensing income and milestone payments from FYB202. Lower research and development costs due to project progress and capitalization of development expenses contributed to the improved results. Formycon confirmed its full‑year guidance of €60–70m revenue and group EBITDA of €0–10m and completed the clinical development of FYB206. » Altro su de.investing.com
Formycon improves preliminary results for fiscal year 2025 and schedules audited annual financial statements

Formycon reports a significant improvement in its preliminary operating figures for 2025: group EBITDA improves from -€12m to around -€4m, and group adjusted EBITDA from -€7m to around -€2m. Group revenue remains unchanged at around €45m. Group working capital is about €70m (previously ~€73m, guidance €55–65m). Publication of the audited annual financial statements and an analyst conference are scheduled for 22 April 2026. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, Formycon ha già distribuito 0,26€ di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Formycon ha registrato ricavi pari a 25,76M€ e un utile netto di −14,63M€

(EUR)	giu 2026	YoY
Ricavi	+25,76M	-
Utile lordo	−3,04M	-
Utile netto	−14,63M	-
EBITDA	−4,98M	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+344,62M€
Numero di azioni	17,67M
Massimo/minimo a 52 settimane	+80,20€ - +18,70€
Dividendi	No
Beta	0,72
Rapporto P/E	−13,69
Rapporto PEG	−0,09
Rapporto P/B	+0,89
Rapporto P/S	+5,61

Profilo aziendale

Die Formycon AG entwickelt und vermarktet Biosimilar-Produkte. Die Produktpipeline umfasst FYB201, einen Biosimilar-Kandidaten für Lucentis, ein Augenarzneimittel, das zur Behandlung der neovaskulären altersbedingten Makuladegeneration und anderer schwerer Augenerkrankungen eingesetzt wird; FYB202, ein Biosimilar-Kandidat für Stelara, ein Biopharmazeutikum, das zur Behandlung von Entzündungskrankheiten wie mittelschwerer bis schwerer Schuppenflechte sowie zur Behandlung von Morbus Crohn und Colitis ulcerosa eingesetzt wird und sich in der klinischen Prüfung der Phase III befindet; und FYB203, ein Biosimilar-Kandidat für Eylea zur Behandlung der neovaskulären altersbedingten Makuladegeneration und anderer Augenkrankheiten, der sich in der klinischen Prüfung der Phase III befindet. Das Unternehmen entwickelt außerdem FYB206 und FYB207, ein antivirales Medikament zur Behandlung von COVID-19. Es hat eine Kooperationsvereinbarung mit der Leukocare AG zur Entwicklung stabiler Formulierungen für verschiedene Kandidaten in seiner Produktpipeline. Das Unternehmen war früher unter dem Namen Nanohale AG bekannt und änderte 2012 seinen Namen in Formycon AG. Die Formycon AG wurde 1999 gegründet und hat ihren Hauptsitz in Planegg, Deutschland.

Nome	Formycon
CEO	Stefan Glombitza
Sede centrale	Planegg, bv Germania
Sito web	formycon.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	04/01/2011
Dipendenti	203